Table 4 The mean and median likelihood of each scenario
Mean likelihood (median) | |||
|---|---|---|---|
All respondents (n = 29) | Only familiar and experts (n = 23) | ≥ 1 year experience (n = 10) | |
Base case scenario | |||
“Base case” | 54.3% (50%) | 51.8 (45%) | 55% (55%) |
“What if” scenarios | |||
“Competition” | 46.4% (50%) | 47.6% (50%) | 42.5% (30%) |
“TIL more effective” | 51.9% (50%) | 52.4% (50%) | 52% (50%) |
“Biomarker” | 36.7% (35%) | 38.3% (35%) | 39.5% (35%) |
“TCR therapy” | 32.0% (30%) | 29.3% (25%) | 22.5% (20%) |
“Patients unconvinced” | 52.9% (60%) | 53.6% (63%) | 45% (50%) |
“2nd line treatment” | 52.8% (50%) | 53.7% (50%) | 53.5% (50%) |
“3rd line treatment” | 54.5% (50%) | 56.8% (50%) | 67% (68%) |
“Combination therapy” | 57.3% (63%) | 56.7% (60%) | 57% (60%) |
“Clinicians unconvinced” | 50.6% (50%) | 51.6% (50%) | 51% (50%) |
“Low cost competition” | 29.5% (20%) | 28.7% (15%) | 27.5% (23%) |
“Influence by companies” | 50.00% (58%) | 51.7% (55%) | 49% (55%) |
“Less IL2 treatment” | 35.9% (50.%) | 39.1% (50%) | 40.5% (50%) |
“TIL production outsourced” | 53.0% (50%) | 51.5% (50%) | 44% (45%) |
“Automatic TIL production” | 58.4% (63%) | 57.0% (60%) | 62% (70%) |